Atossa Genetics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Beats Expectations By $0.30 EPS

Atossa Genetics (NASDAQ:ATOS) released its quarterly earnings results on Tuesday. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.30, FiscalAI reports.

Atossa Genetics Price Performance

Shares of ATOS traded down $0.14 during mid-day trading on Thursday, reaching $1.90. 72,977 shares of the company’s stock traded hands, compared to its average volume of 112,193. The stock has a market cap of $18.91 million, a P/E ratio of -0.61 and a beta of 1.38. The stock’s 50-day moving average is $2.35 and its two-hundred day moving average is $3.70. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $14.85.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Atossa Genetics in a research report on Tuesday, September 8th. Wall Street Zen upgraded shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Atossa Genetics presently has an average rating of “Moderate Buy” and a consensus target price of $20.33.

About Atossa Genetics

Atossa Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast-related conditions. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer. Atossa’s lead program is (Z)-endoxifen, an oral selective estrogen receptor modulator being investigated primarily for estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.